Claro® (florfenicol, terbinafine, mometasone furoate) Otic Solution
Claro is the first FDA-approved, veterinarian-administered, single-dose treatment regimen for canine otitis externa. Just one dose per infected ear, administered by you, removes the uncertainty of client compliance.
Why choose Claro?
Administered through a single-dose regimen in-clinic, Claro reduces the challenges of administering doses at home and eliminates the uncertainty of client compliance.
The first FDA-approved, veterinarian-administered, single-dose treatment for canine otitis externa.
The same 1-ml dose treats dogs of all sizes.
Provides up to 30 days' duration of effect
Eliminates concerns of missed or incorrectly applied doses.
"The owners are relieved."
"Their confidence grows in you."
Hear why veterinarians worldwide true Claro to treat OE, aid in compliance and bring relief to both dogs and their owners.
Important information about Claro
The treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Florfenicol, Terbinafine and Mometasone furoate
Single-application solution
One Size Loves All
A single, 1-mL of Claro in each infected ear treats dogs of all sizes
Claro® (florfenicol, terbinafine, mometasone furoate) Otic Solution Resources
Claro Pet Owner Brochure
Discover convenience without compromise when using Claro for dogs.
Contact your Elanco sales representative to discover how you can get Claro for dogs today.
Indication
Claro® is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Important Safety Information
CLARO should be administered by veterinary personnel. Wear eye protection when administering CLARO. Splatter may occur if the dog shakes its head following administration. Do not use in dogs with known tympanic membrane perforation. The integrity of the tympanic membrane should be confirmed before administering the product. CLARO has been associated with rupture of the tympanic membrane. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Owners should be aware that adverse reactions may occur following administration of CLARO and should be instructed to observe the dog for signs such as ear pain and irritation, vomiting, head shaking, head tilt, incoordination, eye pain and ocular discharge. Owners should also be informed that splatter may occur if the dog shakes its head following administration of CLARO which may lead to ocular exposure. Eye injuries, including corneal ulcers, have been reported in humans and dogs associated with head shaking and splatter following administration. Owners should be careful to avoid ocular exposure.
(For full prescribing information see Claro package insert.)
